Cytarabine and Acute promyelocytic leukaemia differentiation syndrome - a phase IV clinical study of FDA data

Summary:

Acute promyelocytic leukaemia differentiation syndrome is reported as a side effect among people who take Cytarabine (cytarabine), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Mitoxantrone, and have Acute promyelocytic leukaemia.

The phase IV clinical study analyzes which people have Acute promyelocytic leukaemia differentiation syndrome when taking Cytarabine. It is created by eHealthMe based on reports of 65,319 people who have side effects when taking Cytarabine from the FDA, and is updated regularly.

What is Cytarabine?

Cytarabine has active ingredients of cytarabine. It is often used in acute myelogenous leukemia (aml) - adult. eHealthMe is studying from 65,358 Cytarabine users. Check the latest studies of Cytarabine.

What is Acute promyelocytic leukaemia differentiation syndrome?

Acute promyelocytic leukaemia differentiation syndrome is found to be associated with 19 drugs and 115 conditions by eHealthMe. Check the latest studies of Acute promyelocytic leukaemia differentiation syndrome.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 15, 2026

65,319 people reported to have side effects when taking Cytarabine.
Among them, 39 people (0.06%) have Acute promyelocytic leukaemia differentiation syndrome.

Could Cytarabine cause Acute promyelocytic leukaemia differentiation syndrome?

Among these 39 people:

How long have people been on Cytarabine when they have Acute promyelocytic leukaemia differentiation syndrome? *

What is the gender of people who have Acute promyelocytic leukaemia differentiation syndrome when taking Cytarabine? *

female: 44.44 %
male: 55.56 %

What is the age of people who have Acute promyelocytic leukaemia differentiation syndrome when taking Cytarabine? *

What are other drugs people take besides Cytarabine? *

Mitoxantrone: 11 people, 28.21%
Etoposide: 10 people, 25.64%
Thioguanine: 8 people, 20.51%
Prednisone: 8 people, 20.51%
Vesanoid: 7 people, 17.95%
Tretinoin: 6 people, 15.38%
Mitoxantrone Hydrochloride: 5 people, 12.82%
Atra: 3 people, 7.69%
Methotrexate: 3 people, 7.69%
Arsenic Trioxide: 3 people, 7.69%

What are other side effects people have besides Acute promyelocytic leukaemia differentiation syndrome? *

Fever: 22 people, 56.41%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 19 people, 48.72%
Infection: 15 people, 38.46%
Haemorrhage (bleeding): 14 people, 35.90%
Death: 13 people, 33.33%
Acute Kidney Failure: 13 people, 33.33%
Pseudotumor Cerebri (increased pressure within the brain in the absence of a tumour): 11 people, 28.21%
Heart Attack: 10 people, 25.64%
Weight Increased: 8 people, 20.51%
Dyspnea (difficult or laboured breathing): 8 people, 20.51%

What are the existing conditions these people have? *

Acute Promyelocytic Leukaemia (cancer of the blood and bone marrow): 34 people, 87.18%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 2 people, 5.13%
Leukocytosis (increased white blood cells): 1 person, 2.56%
Leukaemia Recurrent (repeat cancer of bone marrow or blood cells): 1 person, 2.56%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 2.56%

* Approximation only. Some reports may have incomplete information.

Do you take Cytarabine and have Acute promyelocytic leukaemia differentiation syndrome?

- Check whether Acute promyelocytic leukaemia differentiation syndrome is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cytarabine:

Cytarabine (65,358 reports)

Acute promyelocytic leukaemia differentiation syndrome treatments and more:

Acute promyelocytic leukaemia differentiation syndrome (272 reports)

How severe was Acute promyelocytic leukaemia differentiation syndrome and when was it recovered:

Acute promyelocytic leukaemia differentiation syndrome in Cytarabine

Expand to all the drugs that have ingredients of cytarabine:

Acute promyelocytic leukaemia differentiation syndrome and drugs with ingredients of cytarabine

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cytarabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Acute promyelocytic leukaemia differentiation syndrome:

Acute promyelocytic leukaemia differentiation syndrome (19 drugs)

Browse all the conditions that are associated with Acute promyelocytic leukaemia differentiation syndrome:

Acute promyelocytic leukaemia differentiation syndrome (115 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cytarabine (the active ingredients of Cytarabine) and Cytarabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.